GWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients

Troels K. BergmannSchool of Pharmacy, University of Queensland, Brisbane, Australia;Clinical Pharmacology, Institute of Public Health, University of Southern Denmark, Odense, DenmarkCorrespondence[email protected]

Werner VachClinical Epidemiology, Institute of Medical Biometry and Medical Informatics, University Medical Center, Freiburg, Germany

Søren FeddersenDepartment of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark

Lise EckhoffDepartment of Oncology, Odense University Hospital, Odense, Denmark

Henrik GréenClinical Pharmacology, Department of Medical and Health Sciences, Linköping University, Linköping, Sweden;Science for Life Laboratory, School of Biotechnology, Division of Gene Technology, Royal Institute of Technology, Solna, Sweden

Jørn HerrstedtDepartment of Oncology, Odense University Hospital, Odense, Denmark

Kim BrosenClinical Pharmacology, Institute of Public Health, University of Southern Denmark, Odense, Denmark

show all

Click to increase image sizeClick to decrease image size

Acknowledgements

We wish to acknowledge the AGO Ovarian Cancer study group in Wiesbaden, Germany and The Nordic Society of Gynaecologic Oncology, Clinical Trial Unit, Odense, Denmark for making available the clinical data from the AGO-OVAR-9 study and the NSGO-OC9804 (TEC) study.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

This work was supported by the Danish Ministry of Interior Affairs and Health (2001–2007) [J.nr 2006-12103-276], the European Commission [CHEMORES LSHC-CT-2007-037665], the Swedish Cancer Society, Swedish Research Council, and the Danish Research Agency [J.nr 271-05-0266].

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

GWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients

Information for

Open access

Opportunities

Help and information

GWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients

Acknowledgements

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature